Skip to main

Impact case study database

The impact case study database allows you to browse and search for impact case studies submitted to the REF 2021. Use the search and filters below to find the impact case studies you are looking for.
Impact case study database FAQs
Download all impact case studies (spreadsheet)
Download all impact case studies (spreadsheet) (generating)
Back

PARP inhibition in BRCA-mutated cancer: improved survival for ovarian, breast, pancreatic and prostate cancer patients

Download case study PDF
Submitting institution
Institute of Cancer Research: Royal Cancer Hospital (The)
Unit of assessment
5 - Biological Sciences
Summary impact type
Technological
Request cross-referral to
-
Is this case study continued from a case study submitted in 2014?
No

1. Summary of the impact

2. Underpinning research

3. References to the research

4. Details of the impact

5. Sources to corroborate the impact

Additional contextual information

Grant funding

Grant number Value of grant
BBC024X (internal) £30,872,915
CTR-Q3-Y1 £5,900,000
CTR-Q3-Y2 £23,200,000
MRC103X (internal) £233,620
CRC369X (internal) £176,524
IS-BRC-1215-20021 £43,074,315
ACRF 02/03 £0
SUC001X (internal) £1,066,784
C347/A13907 £222,788
C347/A8363 £2,073,409
C347/A14276 £2,459,598
C347/A24439 £2,042,986
None given £530,886
CTR-Q4 £39,327,814
Countries
  • US
  • Austria
  • Belgium
  • Bulgaria
  • Croatia
  • Cyprus
  • Czechia
  • Denmark
  • Estonia
  • Finland
  • France
  • Germany
  • Greece
  • Hungary
  • Ireland
  • Italy
  • Latvia
  • Lithuania
  • Luxembourg
  • Malta
  • Netherlands
  • Poland
  • Portugal
  • Romania
  • Slovakia
  • Slovenia
  • Spain
  • Sweden
  • Iceland
  • Liechtenstein
  • Norway
  • UK
  • Canada
  • Japan
  • Brazil
  • China
Formal partners
  • KuDOS
  • AstraZeneca
Funding programmes
  • Breast Cancer Now (previously Breakthrough Breast Cancer) Centre Core Grant 2003 to 2010
  • Breast Cancer Now (previously Breakthrough Breast Cancer) Centre Core Grant 2010 to 2011
  • Breast Cancer Now (previously Breakthrough Breast Cancer) Centre Core Grant 2011 to 2015
  • Medical Research Council: Identification and development of synthetic lethal strategies and predictive biomarkers for therapy for MMR Deficient Colorectal Cancer
  • Cancer Research UK: Sensitivity to PARP Inhibition mediated by PTEN deficiency: investigating a novel therapeutic approach
  • The National Institute for Health Research Biomedical Research Centre at The Royal Marsden and The Institute of Cancer Research (2017)
  • Breast Cancer Now (previously Breakthrough Breast Cancer) Avon Clinical Fellow
  • Stand Up To Cancer: An Integrated Approach to Targeting Breast Cancer
  • Cancer Research UK: Use of mouse models for identification and functional validation of mutated genes contributing to BRCA1/2 tumourigenesis
  • Cancer Research UK: Cancer Susceptibility Genes (2008)
  • Cancer Research UK: Cancer Susceptibility Genes (2012)
  • Cancer Research UK: Cancer Susceptibility Genes (2017)
  • High-throughput identification and evaluation of new breast cancer genes from GWAS.
  • Breast Cancer Now (previously Breakthrough Breast Cancer) Centre Core Grant 2015 to 2021
Global research identifiers
  • grid.458394.7
  • grid.420006.0
  • grid.11485.39
  • grid.451056.3
  • grid.430427.6
  • grid.431143.0
Name of funders
  • Breast Cancer Now (previously Breakthrough Breast Cancer)
  • Medical Research Council
  • Cancer Research UK (previously Cancer Research Campaign)
  • National Institute for Health Research
  • Stand Up To Cancer (part of the Entertainment Industry Foundation)
  • National Health and Medical Research Council of Australia
Researcher ORCIDs
  • 0000-0003-1446-7878
  • 0000-0002-3226-0515
  • 0000-0001-8715-2901
  • 0000-0003-3313-3857